Replies to post #33910 on Humanigen Inc (HGENQ)

[cowtown jay]

I only provided a link which enables us to hear exactly what Durrant said about this three weeks ago at the Oppenheimer presentation.

The NIH trial of the first 200 patients was not likely retrospectively reviewed for efficacy based on the baseline characteristic of < 150 mg/L of CRP. This would be a reinterpretation of existing data which is a basis for an FDA reversal. I don't know if NIH-sponsored trials need a peer-review, or not. But if it confirms what we have reported, I hope it leads to an EUA approval.